Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Brazilian regulators authorize Sorrento Phase 2 clinical trial of COVI-MSC in COVID-19 long-haulers

By Brian Buntz | January 19, 2022

Sorrento TherapeuticsSorrento Therapeutics (NSDQ:SRNE) has received the go-ahead from the Brazilian Health Regulatory Agency (ANVISA) for a Phase 2a study involving its COVI-MSC allogeneic adipose-derived mesenchymal stromal cells.

The company hopes the experimental treatment will benefit patients with so-called “long COVID,” a syndrome linked with a variety of symptoms ranging from fatigue to pulmonary compromise.

The study’s primary outcome measure will be change in six-minute walk distance at day 60.

In addition, the study will several secondary outcome measures, including relief of symptoms, change in pulmonary function and change in biomarker levels at day 30 and day 60

The study will test up to three infusions of COVI-MSC in approximately 60 participants.

“We expect this next Phase 2 study to confirm the clinical benefits for long-hauler patients. Long-hauler syndrome is likely to be the next major challenge for medical systems in a post-COVID era, and we intend to be the leaders in addressing this future unmet need,” said Dr. Henry Ji, CEO of Sorrento, in a statement.

Brazilian regulators authorize Sorrento Phase 2 clinical trial of COVI-MSC in COVID-19 long-haulers

Sorrento Therapeutics (NSDQ:SRNE) has received the go-ahead from the Brazilian Health Regulatory Agency (ANVISA) for a Phase 2a study involving its COVI-MSC allogeneic adipose-derived mesenchymal stromal cells.

The company hopes the experimental treatment will benefit patients with so-called “long COVID,” a syndrome linked with a variety of symptoms ranging from fatigue to pulmonary compromise.

The study’s primary outcome measure will be change in six-minute walk distance at day 60.

In addition, the study will several secondary outcome measures, including relief of symptoms, change in pulmonary function and change in biomarker levels at day 30 and day 60

The study will test up to three infusions of COVI-MSC in approximately 60 participants.

“We expect this next Phase 2 study to confirm the clinical benefits for long-hauler patients. Long-hauler syndrome is likely to be the next major challenge for medical systems in a post-COVID era, and we intend to be the leaders in addressing this future unmet need,” said Dr. Henry Ji, CEO of Sorrento, in a statement.


Filed Under: Oncology
Tagged With: COVI-MSC, covid-19, Sorrento Therapeutics
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
AstraZeneca
Imfinzi with chemotherapy gets FDA priority review for locally advanced or metastatic biliary tract cancer
Novartis
Novartis reveals positive Phase 3 data for tislelizumab plus chemotherapy in esophageal cancer
AstraZeneca/Daiichi-Sankyo
AstraZeneca and Daiichi Sankyo win new breakthrough therapy designation for Enhertu

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50